

A NEW METHOD FOR THE SYNTHESIS OF SOME 9- β -D-ARABINOFURANOSYLPURINES
BY A COMBINATION OF CHEMICAL AND ENZYMATIC REACTIONS¹⁾

Hirokazu Morisawa*, Takashi Utagawa, Takeshi Miyoshi,
Fumihiro Yoshinaga, Akihiro Yamazaki, and Koji Mitsugi

Central Research Laboratories, Ajinomoto Co., Inc.


1-1 Suzuki-cho, Kawasaki-ku, Kawasaki, 210, Japan.

Summary: An enzymatic transarabinylation between 2-chlorohypoxanthine and 1- β -D-arabinofuranosyluracil gave 9- β -D-arabinofuranosyl-2-chlorohypoxanthine which was chemically converted to 9- β -D-arabinofuranosylguanine and its derivatives.

The antiviral or antitumor activity of 9- β -D-arabinofuranosylpurines or the corresponding nucleotides has generated considerable interest.²⁾ Although the syntheses of 9- β -D-arabinofuranosylpurines have been achieved by a sugar-base coupling reaction,³⁾ by a cleavage reaction of 8,2'-anhydro-8-oxy-9- β -D-arabinofuranosylpurines⁴⁾ or by a transformation of oxazolidinethione derivative,⁵⁾ there remain some definite practical limitations in these approaches because of low-yielding, laborious and time-consuming process.

We now report a new strategy for the utilization of enzymes as catalysts in the synthetic process of 9- β -D-arabinofuranosylpurines. More recently we have shown⁶⁾ that the antiviral agent, 9- β -D-arabinofuranosyladenine (5, ara-A), can be easily obtained by a novel enzymatic transarabinylation between adenine (3) and 1- β -D-arabinofuranosyluracil (2). This procedure was extended successfully to the synthesis of 9- β -D-arabinofuranosyl-2-chlorohypoxanthine (6), which was important as an intermediate for the preparation of biologically interesting 9- β -D-arabinofuranosylpurines.

When 2-chlorohypoxanthine (4) (0.1 mol) and compound 2 (0.3 mol), readily obtained via 2,2'-anhydro- β -D-arabinofuranosyluracil⁷⁾ from uridine (1), were incubated with intact cells of *Enterobacter aerogenes* (500 g as wet paste) in 10 l of 25 mM potassium phosphate buffer (pH 7.0) for 12 hours at 60°C, compound 6 was produced specifically and, after removing the bacterial cells, isolated by column chromatography (Dowex 1 x 4) in 34% yield (based on 4). This compound had m.p. 208-209°C (dec.) and showed nmr [(DMSO-d₆) δ 8.06 (H-8), 6.02 (H-1', J_{1',2'}=4.5 Hz)] and UV spectra [$\lambda_{\text{max}}^{\text{pH 1}}$ 253 nm (ϵ =12000), $\lambda_{\text{max}}^{\text{pH 13}}$ 257 nm (ϵ =13600)], the latter of which was identical with those previously reported.⁸⁾



Compound 6 was treated with methanolic ammonia in an autoclave at 150°C for 4 hours to give 9-β-D-arabinofuranosylguanine (7, ara-G) in 85% yield, which had m.p. >300°C (darkens at 275°C), nmr [(DMSO-d₆) δ 7.77 (H-8), 6.04 (H-1', J_{1',2'}=3.9 Hz)] and UV spectra [$\lambda_{\max}^{\text{pH } 1}$ 257 nm ($\epsilon=12900$), 278 nm (sh. $\epsilon=8700$), $\lambda_{\max}^{\text{pH } 13}$ 259 nm ($\epsilon=12100$), 267 nm ($\epsilon=12300$)], which were the same with those reported earlier.^{4b,8,9} Compound 7 has been reported to have a significant antiviral activity.^{2a}

Substitution of methylamine and ethylamine for ammonia in the synthesis of ara-G similarly afforded 9-β-D-arabinofuranosyl-N²-methylguanine (8) and -N²-ethylguanine (9) in 47 and 58% yields, respectively. Compound 8 had m.p. >300°C; nmr (DMSO-d₆) δ 7.86 (H-8), 6.08 (H-1', J_{1',2'}=4.2 Hz), 2.83 (N-CH₃); UV $\lambda_{\max}^{\text{pH } 1}$ 261 nm ($\epsilon=13800$), 284 nm (sh. $\epsilon=7400$), $\lambda_{\max}^{\text{pH } 13}$ 259 nm ($\epsilon=11600$), 272 nm (sh. $\epsilon=10400$). Compound 9 had m.p. 216-217°C; nmr (DMSO-d₆) δ 7.60 (H-8), 5.90 (H-1', J_{1',2'}=4.2 Hz), 3.33 (N-CH₂-CH₃), 1.16 (N-CH₂-CH₃); UV $\lambda_{\max}^{\text{pH } 1}$ 261.5 nm ($\epsilon=14400$), 285 nm (sh. $\epsilon=7400$), $\lambda_{\max}^{\text{pH } 13}$ 260 nm ($\epsilon=12000$), 272 nm (sh. $\epsilon=10700$).

Acetylation of 7 with acetic anhydride in pyridine gave the corresponding triacetate (10) (m.p. 216-218°C) in 88% yield, which was further heated with phosphorus pentasulfide in pyridine for 4 hours, affording 6-thio derivative (12) (m.p. 247-248°C) in 72% yield. Deacetylation of 12 with methanolic ammonia gave 9-β-D-arabinofuranosyl-6-thioguanine (14) in 60% yield, which has been reported to show a potent antitumor activity.¹⁰ This compound had m.p. 250°C dec. (darkens at 210°C) and showed nmr [(DMSO-d₆) δ 7.95 (H-8), 5.95 (H-1', J_{1',2'}=4.2 Hz)] and UV spectra [$\lambda_{\max}^{\text{pH } 1}$ 264 nm ($\epsilon=7800$), 351 nm ($\epsilon=20700$), $\lambda_{\max}^{\text{pH } 13}$ 252 nm ($\epsilon=12000$), 270 nm (sh. $\epsilon=7000$), 320.5 nm ($\epsilon=17900$)]. Although $\lambda_{\max}^{\text{pH } 1}$ (351 nm at pH 1) of 14 was slightly different from that previously reported,¹⁰ it was the same with that of thioguanosine.

By the same manner, 9-β-D-arabinofuranosyl-N²-methyl-6-thioguanine (15) was also obtained via the triacetate (11) (m.p. 281-283°C) of 8 and its 6-thio derivative (13), m.p. 290°C (dec.), in 33% overall yield. Compound 15 had m.p. >300°C (darkens at 235°C); UV $\lambda_{\max}^{\text{pH } 1}$ 270 nm ($\epsilon=10200$), 356 nm ($\epsilon=18700$), $\lambda_{\max}^{\text{pH } 13}$ 258 nm ($\epsilon=14000$), 277 nm (sh. $\epsilon=9400$), 324 nm ($\epsilon=14500$); nmr (DMSO-d₆) δ 7.90 (H-8), 6.05 (H-1', J_{1',2'}=4.2 Hz), 2.85 (N-CH₃).

Thus the present methodology by a combination of chemical and enzymatic reactions seems to be very promising to synthesize biologically important 9-β-D-arabinofuranosylpurines with ease and on a large scale.

Acknowledgment

We thank Dr. Takekazu Akashi, the Director of the Central Research Laboratories, for his helpful advice and encouragement.

References

1. This work has been presented at the Seventh Symposium on Nucleic Acids Chemistry, October 26, 1979, Okayama, Japan.
H. Morisawa, T. Utagawa, T. Miyoshi, N. Kashima, T. Nakamatsu, S. Yamanaka, and A. Yamazaki, *Nucleic Acids Res., Symposium Series*, 6, S25 (1979).
2. a) G.B. Elion, J.L. Rideout, P. de Miranda, P. Collins, and D.J. Bauer, *Ann. N.Y. Acad. Sci.*, 255, 468 (1975);
b) S.S. Cohen, *Medical Biology*, 54, 299 (1976).
3. C.P.J. Glaudemans and H.G. Fletcher, Jr., *J. Org. Chem.*, 28, 3004 (1963).
4. a) M. Ikehara and Y. Ogiso, *Tetrahedron*, 28, 3695 (1972);
b) J.B. Chattopadhyaya and C.B. Reese, *Synthesis*, 908 (1978).
5. R. Ranganathan, *Tetrahedron Lett.*, 1185 (1975).
6. T. Utagawa, H. Morisawa, T. Miyoshi, F. Yoshinaga, A. Yamazaki, and K. Mitsugi, *FEBS Lett.*, in press.
7. H. Komura, T. Yoshino and Y. Ishido, *Bull. Chem. Soc. Japan*, 46, 550 (1973).
8. E.J. Reist and L. Goodman, *Biochemistry*, 3, 15 (1964).
9. M. Ikehara, T. Maruyama, and T. Watanabe, *J. Carbohyd. Nucleosides Nucleotides*, 3, 149 (1976).
10. W.W. Lee, A.P. Martinez, R.W. Blackford, U.J. Bartuska, E.J. Reist, and L. Goodman, *J. Med. Chem.*, 14, 819 (1971).

(Received in Japan 5 November 1979)